WeTrials
Recruiting

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

What is this study?

This study tests a new experimental medication called EIS-12656, both on its own and mixed with other targeted cancer drugs, for people with advanced solid tumors. Researchers want to find the safest dose and see if this new treatment can help shrink tumors that have specific genetic changes.

Who can participate?

You might be able to join if you have advanced cancer that has grown or spread, and your tumor has specific genetic flaws related to how cells repair DNA. Participants also need to have healthy organ function and be able to travel to the study location.

What will happen?

You will receive the study medication, either by itself or along with another approved cancer treatment, while doctors closely monitor your health and safety. You will undergo regular check-ups and imaging scans to see how your body and your tumor respond to the treatment.

Where and when?

The study is currently actively recruiting participants in Houston, Texas, United States. More locations may become available in the future.

Key Points
  • 1Tests a new experimental drug called EIS-12656 for advanced solid tumors
  • 2Looks for the right dose and checks for safety and effectiveness
  • 3Requires specific genetic changes in your tumor related to DNA repair

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.